全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Ligang Xing , Yuhui Zhang , Jidong Yang
来源:[J].Biochemical and Biophysical Research Communications(IF 2.406), 2019, Vol.514 (1), pp.134-139
摘要:Abstract(#br)Here, we describe a study of screen characterization of aptamers targeting the chiral drug ephedrine using the non-immobilized graphene oxide (GO) SELEX. The improved method of long and short chains was here used to prepare the ssDNA library. The Resonance Rayle...
作者:... Feifei Teng , Zhaoqin Huang , Ligang Xing
来源:[J].Clinical Lung Cancer(IF 2.038), 2018
摘要:Abstract(#br)Introduction(#br)Checkpoint blockades have entered routine clinical use for non-small cell lung cancer (NSCLC). However, there were some differences in efficacy and response predictors for anti-PD-1 antibodies between squamous (SQ)and non-squamous (non-SQ) NSCLC. The...
作者:... Shuai Wang , Ligang Xing , Jinming Yu
来源:[J].Cancer Letters(IF 4.258), 2018, Vol.418, pp.1-9
摘要:Abstract(#br)Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD-1/PD-L1) pathway displayed striking and durable clinical responses in patients with non-small-cell lung cancer (NSCLC). However, it is still undefined about the efficacy of PD-1/PD...
作者:... Feifei Teng , Ligang Xing , Jinming Yu
来源:[J].Cancer Letters(IF 4.258), 2017, Vol.405, pp.29-37
摘要:Abstract(#br)PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for second-line treatment of non-small cell lung cancer (NSCLC). Based on the promising results of Keynote-024 presented so far, pembrolizumab has been approved as first-line treatment for advanc...
作者:... Xianguang Zhao , Ligang Xing , Wanqi Zhu
来源:[J].Radiotherapy and Oncology(IF 4.52), 2019, Vol.137, pp.186-191
摘要:Abstract(#br)Background and purpose(#br)This trial investigated whether epigallocatechin-3-gallate (EGCG), a radioprotector, could be effective in the prevention and treatment of acute radiation-induced esophagitis (ARIE).(#br)Methods and materials(#br)This is a phase II study of...
作者:... Wenwu Li , Ligang Xing , Jinming Yu
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.11 (1)
摘要:The identification of surgical non-small cell lung cancer (NSCLC) patients with poor prognosis is a priority in clinical oncology because of their high 5-year mortality. This meta-analysis explored the prognostic value of maximal standardized uptake value (SUVmax), metabolic tumo...
作者:... Xianguang Zhao , Ligang Xing , Jinming Yu
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.11 (6)
摘要:To observe the early change of metabolic tumor heterogeneity during chemoradiotherapy and to determine its prognostic value for patients with locally advanced non-small cell lung cancer (NSCLC).From January 2007 to March 2010, 58 patients with NSCLC were included who were receive...
作者:... Xiaoting Chen , Ligang Xing , Jinming Yu
来源:[J].Radiotherapy and Oncology(IF 4.52), 2015, Vol.114 (3), pp.351-356
摘要:Abstract(#br)Background(#br)Acute radiation-induced esophagitis (ARIE) is one of main toxicities complicated by thoracic radiotherapy, influencing patients’ quality of life and radiotherapy proceeding seriously. It is difficult to be cured rapidly so far. Our phase I trial p...
作者:... Feifei Teng , Ligang Xing , Jinming Yu
来源:[J].Cancer Treatment Reviews(IF 6.024), 2015, Vol.41 (10), pp.868-876
摘要:Abstract(#br)Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignanci...
作者:Ligang Xing , Xiaorong Sun ...
来源:[J].Radiotherapy and Oncology(IF 4.52), 2009, Vol.92 (3), pp.345-352
摘要:Abstract(#br)Purpose(#br)To test the hypothesis that, with 5-fluorocytosine (5-FC) treatment, the co-expression of cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT) can lead to greater radiosensitization and bystander effect than CD-expression alone.(#br)Me...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×